PC

Pcas SAPAR Pcas Stock Report

Last reporting period 30 Jun, 2023

Updated —

Last price

Market cap $B

0.125

Micro

Exchange

XPAR - Euronext Paris

PCA.PA Stock Analysis

PC

Uncovered

Pcas SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-24/100

Low score

Market cap $B

0.125

Dividend yield

Shares outstanding

13.742 B

PCAS SA engages in the development, manufacture, and sale of chemicals. The company is headquartered in Ecully, Auvergne-Rhone-Alpes. The company operates through nine production sites and two main business units, Pharma Synthesis and Fine & Specialty Chemicals. Pharma Synthesis unit specializes in active pharmaceutical ingredients (API), intermediates and building blocks, and early phase services, among others. Fine & Specialty Chemicals unit focuses on custom manufacturing and proprietary products, such as fragrance, flavor ingredients, imaging and microelectronics chemicals. The firm operates several subsidiaries, including Saint-Jean Photochimie, Societe Bearnaise de Synthese, Expansia, PCAS BioMatrix Inc, based in Canada, and PCAS Finland Oy, based in Finland, among others.

View Section: Eyestock Rating